Premium
Melatonin attenuates epidermal growth factor‐induced cathepsin S expression in ARPE‐19 cells: Implications for proliferative vitreoretinopathy
Author(s) -
Yang ShunFa,
Chen YongSyuan,
Chien HsiangWen,
Wang Kai,
Lin ChiaLiang,
Chiou HuiLing,
Lee ChiaYi,
Chen PeiNi,
Hsieh YiHsien
Publication year - 2020
Publication title -
journal of pineal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 131
eISSN - 1600-079X
pISSN - 0742-3098
DOI - 10.1111/jpi.12615
Subject(s) - melatonin , epidermal growth factor , proliferative vitreoretinopathy , pi3k/akt/mtor pathway , protein kinase b , ly294002 , motility , wortmannin , biology , microbiology and biotechnology , cell growth , mapk/erk pathway , signal transduction , cancer research , chemistry , endocrinology , cell culture , retinal , biochemistry , retinal detachment , genetics
Abnormal proliferation and motility of retinal pigment epithelial cells leads to proliferative vitreoretinopathy (PVR). Melatonin is a known effective antitumour and anti‐invasive agent, but whether it affects the formation and underlying mechanisms of PVR remains unclear. In this study, the results of the MTT assay, colony formation and propidium iodide (PI) staining with flow cytometry revealed that melatonin dose dependently inhibited epidermal growth factor (EGF)‐induced proliferation of human ARPE‐19 cells. Furthermore, melatonin reduced EGF‐induced motility by suppressing cathepsin S (CTSS) expression. Pretreatment with ZFL (a CTSS inhibitor) or overexpression of CTSS (pCMV‐CTSS) significantly inhibited EGF‐induced cell motility when combined with melatonin. Epidermal growth factor induced the phosphorylation of AKT(S473)/mTOR (S2448) and transcription factor (c‐Jun/Sp1) signaling pathways. Pretreatment of LY294002 (a PI3K inhibitor) or rapamycin (an mTOR inhibitor) markedly reduced EGF‐induced motility and p‐AKT/p‐mTOR/c‐Jun/Sp1 expression when combined with melatonin. Taken together, these data indicate that melatonin inhibited EGF‐induced proliferation and motility of human ARPE‐19 cells by activating the AKT/mTOR pathway, which is dependent on CTSS modulation of c‐Jun/Sp1 signalling. Melatonin may be a promising therapeutic drug against PVR.